S
Sabrina Spinosa-Guzman
Researcher at Tibotec
Publications - 22
Citations - 1620
Sabrina Spinosa-Guzman is an academic researcher from Tibotec. The author has contributed to research in topics: Darunavir & Ritonavir. The author has an hindex of 13, co-authored 22 publications receiving 1588 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials
Bonaventura Clotet,Nicholas Bellos,Jean-Michel Molina,David A. Cooper,Jean-Christophe Goffard,Adriano Lazzarin,Andrej Wöhrmann,Christine Katlama,Timothy J. Wilkin,Richard Haubrich,Calvin J. Cohen,Charles Farthing,Dushyantha Jayaweera,Martin Markowitz,Peter Ruane,Sabrina Spinosa-Guzman,Eric Lefebvre +16 more
TL;DR: Efficacy responses with darunavir-ritonavir 600/100 mg twice daily plus optimised background regimen were greater than those with control PI and were sustained to at least week 48, with favourable safety and tolerability in treatment-experienced patients.
Journal ArticleDOI
Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.
Roberto Ortiz,Edwin DeJesus,Homayoon Khanlou,Evgeniy Voronin,Jan van Lunzen,Jaime Andrade-Villanueva,Jan Fourie,Sandra De Meyer,Martine De Pauw,Eric Lefebvre,Tony Vangeneugden,Sabrina Spinosa-Guzman +11 more
TL;DR: DRV/r 800/100 mg qd was non-inferior to LPV/ r 800/200 mg at 48 weeks, with a more favorable safety profile, and offers a new effective and well tolerated once-daily, first-line treatment option for treatment-naive patients.
Journal ArticleDOI
Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial
José Valdez Madruga,Daniel S Berger,Marilyn McMurchie,Fredy Suter,Denes Banhegyi,Kiat Ruxrungtham,Dorece Norris,Eric Lefebvre,Marie Pierre de Béthune,Frank Tomaka,Martine De Pauw,Tony Vangeneugden,Sabrina Spinosa-Guzman +12 more
TL;DR: In lopinavir-naive, treatment-experienced patients, darunavir-ritonavir was non-inferior to lop Scandinavian-rit onavir treatment in terms of the virological endpoint, and should therefore be considered as a treatment option for this population.
Journal ArticleDOI
The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers.
Vanitha Sekar,Dries Kestens,Sabrina Spinosa-Guzman,Martine De Pauw,Els De Paepe,Tony Vangeneugden,Eric Lefebvre,Richard M. W. Hoetelmans +7 more
TL;DR: Darunavir/rtv should be administered with food, but exposure to darunavIR is not affected by the type of meal, as no significant differences in dar unavir plasma concentrations were observed between different fed states.
Journal ArticleDOI
Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.
Sandra De Meyer,Erkki Lathouwers,Inge Dierynck,Els De Paepe,Ben van Baelen,Tony Vangeneugden,Sabrina Spinosa-Guzman,Eric Lefebvre,Gaston Picchio,Marie-Pierre de Béthune +9 more
TL;DR: In treatment-experienced, LPV-naive patients, the overall virologic failure rate in the DRV/r arm was low and was associated with limited resistance development, showing that the use of DRv/r in earlier lines of treatment was less likely to lead to cross-resistance to other protease inhibitors compared with LPV/ r.